Clozapine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Clozapine Access in 2026

Clozapine remains the only FDA-approved pharmacotherapy for treatment-resistant schizophrenia (TRS) and is uniquely indicated for reducing recurrent suicidal behavior in schizophrenia and schizoaffective disorder. Despite its demonstrated superiority in TRS, Clozapine has been consistently underutilized — with estimates suggesting that fewer than 5% of eligible patients receive it.

The regulatory landscape changed significantly in 2025, and providers need to understand how these changes affect their prescribing practices and patient access going forward.

Timeline: Key Changes in Clozapine Access

• 1990: FDA approves Clozapine for treatment-resistant schizophrenia
• 2005: FDA mandates Clozapine REMS program (consolidated multiple registry systems)
• 2015-2024: Repeated reports of the REMS creating access barriers; FDA issues temporary enforcement discretion multiple times
• June 13, 2025: FDA officially removes the Clozapine REMS program
• 2026: Post-REMS transition period — pharmacies adjusting to new dispensing protocols

Prescribing Implications After REMS Removal

The removal of the Clozapine REMS has several practical implications for prescribers:

What's Changed

• No prescriber certification required: Prescribers no longer need to enroll in or maintain certification through the Clozapine REMS program
• No patient registration: There's no central database for patient enrollment; prescribers don't need to register patients before writing a prescription
• No pharmacy certification check: Any licensed pharmacy can now stock and dispense Clozapine without special certification
• No dispensing verification system: The centralized system that verified ANC results before dispensing has been deactivated

What Hasn't Changed

• ANC monitoring remains recommended: The prescribing information — including boxed warnings — still recommends monitoring ANC at the same frequency as before (weekly for 6 months, biweekly for 6 months, monthly thereafter)
• Boxed warnings remain: All five boxed warnings (severe neutropenia, orthostatic hypotension/bradycardia/syncope, seizures, myocarditis/cardiomyopathy, and increased mortality in elderly with dementia-related psychosis) are unchanged
• Clinical responsibility: The prescriber retains full clinical responsibility for ordering and reviewing ANC results and making treatment decisions based on them

Practical Recommendation

Even without the REMS, best practice remains to document ANC monitoring in the patient's chart and to withhold Clozapine if ANC falls below 1,500/μL (or 1,000/μL for patients with documented benign ethnic neutropenia). Consider implementing an internal tracking system if your practice doesn't already have one.

Current Availability Picture

Clozapine is not listed on the FDA drug shortage database as of early 2026. Generic tablets are produced by multiple manufacturers, and the primary supply chain is intact.

However, patient reports and pharmacy data indicate ongoing access challenges:

• Many pharmacies — especially chains — have not yet added Clozapine to their regular inventory post-REMS
• Specialty formulations (ODT tablets, oral suspension) remain less widely available
• Rural and underserved areas continue to have fewer stocking pharmacies

The expectation is that pharmacy stocking will improve throughout 2026 as the administrative barriers are fully resolved, but the transition is uneven.

Cost and Access Considerations

Cost should not be a significant barrier for most patients:

• Generic Clozapine tablets: $60-$200/month without insurance (dose-dependent)
• With discount coupons (GoodRx, SingleCare): As low as $42/month
• Medicare/Medicaid: Generally covered with low copays ($0-$35); prior authorization may be required by some plans
• Brand-name Clozaril: $1,500+/month — rarely necessary given generic availability

For patients facing financial barriers, options include:

• Prescription discount cards (GoodRx, SingleCare, RxSaver)
• Patient assistance programs through NeedyMeds and RxAssist
• State Medicaid programs (Clozapine is covered in all state formularies)

For a patient-facing resource on costs, direct patients to our guide on saving money on Clozapine.

Tools and Resources for Providers

Medfinder for Providers

Medfinder's provider tools allow you to check real-time pharmacy availability for Clozapine and other difficult-to-find medications. This can be invaluable when your patient calls to say their pharmacy doesn't have their medication.

FDA Resources

• FDA Clozapine Information Page — current guidance on prescribing and monitoring post-REMS
• FDA Drug Shortage Database — check current shortage status

Clinical Resources

• SMI Adviser (smicaladviser.org) — evidence-based resources for managing clozapine therapy, drug interactions, and monitoring protocols
• Clozapine REMS website (newclozapinerems.com) — now serves as a reference for post-REMS transition information

Looking Ahead

The removal of the REMS represents a pivotal moment for Clozapine access. Prescribers should anticipate:

• Gradual improvement in pharmacy stocking rates throughout 2026
• Potential for increased prescribing now that administrative barriers are reduced
• Continued need for robust ANC monitoring practices at the clinic level
• Possible updates to clinical guidelines reflecting the post-REMS landscape

As access improves, there's an opportunity to increase Clozapine utilization among the estimated 20-30% of schizophrenia patients who meet criteria for treatment resistance but have never been tried on the drug.

Final Thoughts

Clozapine's unique efficacy in TRS is well-established, and the REMS removal should gradually improve access for patients who need it. In the interim, providers can support their patients by understanding the current availability landscape, leveraging tools like Medfinder for providers, and maintaining robust monitoring protocols even without the REMS infrastructure.

For practical guidance on helping patients navigate pharmacy access, see our companion article: How to help your patients find Clozapine in stock. For a patient-oriented view of the shortage landscape, see our Clozapine shortage update for patients.